<DOC>
	<DOCNO>NCT00137774</DOCNO>
	<brief_summary>The purpose study determine effect ( good bad ) bevacizumab temozolomide patient neuroendocrine tumor .</brief_summary>
	<brief_title>Bevacizumab Combination With Temozolomide Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description>Patients receive temozolomide orally daily one week , follow one-week rest period . This one-week on/one week schedule continue duration treatment unless significant side effect develop . Bevacizumab administer intravenously every week . After eight week ( two cycle ) , CT scan perform see treatment affect tumor growth . Bactrim , antibiotic , acyclovir , antiviral medicine , give order help prevent infection . Blood test do every week evaluate side effect . Once study complete , physical exam , vital sign , blood test , CT scan perform . Patients remain study long continue receive benefit treatment serious side effect .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically document locally unresectable metastatic neuroendocrine tumor exclude small cell carcinoma Measurable disease &gt; 1cm spiral compute tomography ( CT ) &gt; 2cm radiographic technique ECOG performance status 02 Life expectancy &gt; 12 week Prior treatment chemotherapy allow Total bilirubin &lt; 2.0mg/dl AST &lt; 5x upper limit normal ( ULN ) Serum creatinine &lt; 2.0mg/dl Absolute neutrophil count &gt; 1,000/mm3 Platelets &gt; 100,000/mm3 International Normalized Ratio ( INR ) &lt; 1.5 Prior treatment temozolomide , decarbazine bevacizumab Clinically apparent central nervous system metastases carcinomatous meningitis Clinically significant cardiovascular disease Major surgery , open biopsy , significant traumatic injury within 28 day Pregnant breastfeed woman Chronic , daily treatment aspirin nonsteroidal antiinflammatory medication Serious , nonhealing wound , ulcer bone fracture Evidence bleed diathesis coagulopathy History disease metabolic dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Metastatic Neuroendocrine Tumor</keyword>
	<keyword>Advanced Neuroendocrine tumor</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Temozolomide</keyword>
</DOC>